AAV9-Follistatin gene therapy for sarcopenia

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 2 Mar 2026: Trial registered, NCT07443826
  2. 1 Jun 2026: Trial started, NCT07443826

The trials

NCT07443826: CALM-AF-AI: Counteracting Age-related Loss of Muscle With AAV-Follistatin Combined With Angiogenesis-Inducing VEGF Plasmid Gene Therapy

State
Under way
Phase
Phase 1 and Phase 2
People
12 planned
Started
1 Jun 2026
Primary completion
30 Sep 2027
Arms
Low-Dose AAV-Follistatin Monotherapy, High-Dose AAV-Follistatin Monotherapy
Results
None posted
  1. 2 Mar 2026: Trial registered
  2. 1 Jun 2026: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

About the treatment

Kind of treatment: Gene therapy.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.